Aclaris Therapeutics, Inc.
corporate_fare Company Profile
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ACRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ACRS spans 8-K, 10-Q, 424B5, S-3ASR.
Recent high-impact activity:
- Aclaris' Bosakitug Misses Phase 2 ADMIRATION Endpoint; Pivots to Oral Kinase and ATI-052 Programs
- Phase 2 Atopic Dermatitis Trial Fails; Aclaris Pivots to ITK Inhibitors and ATI-052
- Aclaris Q3 10-Q: $204.6M Cash, $59.8M Nine-Month Loss, $116M Raised Via ATM
- Aclaris Q3 2026: $204.6M Cash, Runway to 1H 2029, ATI-052 Pivots to EoE
- Aclaris Prices $50M Offering at $3.50, a 7.7% Discount to Last Sale, Alongside Positive ATI-052 Data
Financial Snapshot
Short Interest & Short Volume
4.02 days to coverFINRA reported short interest of 11,572,867 shares in ACRS as of the October 30, 2026 settlement, a 23.0% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 68.4% of ACRS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ACRS, detected from its recent SEC filings · based on capital-structure filings through 2026-10-27.
Priced $50M Underwritten Offering · Net Proceeds and Fees
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →